^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EPCAM expression

    i
    Other names: EPCAM, 17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1, Epithelial cell adhesion molecule
    Entrez ID:
    4072
    Related biomarkers:
    Expression
    Others
    11d
    Comprehensive Analysis and Experimental Validation of HEPACAM2 as a Potential Prognosis Biomarker and Immunotherapy Target in Colorectal Cancer. (PubMed, Curr Gene Ther)
    These findings suggest that HEPACAM2 may serve as a potential prognostic biomarker and immunotherapeutic target for CRC patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    EPCAM expression
    19d
    Characterization of EpCAM-Positive and EpCAM-Negative Tumor Cells in Early-Stage Breast Cancer. (PubMed, Int J Mol Sci)
    scRNA-seq of isolated CTCs and primary tumor partially confirmed this pattern. Therefore, further investigation is imperative to elucidate the prognostic significance of EpCAM-negative and EpCAMlow CTCs.
    Journal • Tumor cell
    |
    CD44 (CD44 Molecule) • EPCAM (Epithelial cell adhesion molecule) • CD24 (CD24 Molecule) • CDH2 (Cadherin 2)
    |
    EPCAM expression
    1m
    Clinicopathologic Characteristics of Trop Family Proteins (Trop-2 and EpCAM) in Gastric Carcinoma. (PubMed, J Gastric Cancer)
    These results highlight the differential expression of Trop-2 and EpCAM and their prognostic implications in GC. The use of meticulously validated antibodies ensured the reliability of our IHC data, thereby offering a robust foundation for future therapeutic strategies targeting Trop family members in GC.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • EPCAM (Epithelial cell adhesion molecule) • MUC5AC (Mucin 5AC) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    MSI-H/dMMR • EGFR positive • EPCAM expression
    1m
    Pressure loading regulates the stemness of liver cancer stem cells via YAP/BMF signaling axis. (PubMed, J Cell Physiol)
    Knockdown of YAP and overexpression of BMF attenuated pressure-mediated stemness and tumorgenicity, while YAP-deficient and BMF-deletion recused pressure-dependent stemness on LCSCs, suggesting the involvement of YAP/BMF signaling axis in this process. Together, our findings provide a potential target for overcoming the stemness of CSCs and elucidate the significance of increased IFP in cancer progression.
    Journal • Cancer stem • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD44 (CD44 Molecule) • EPCAM (Epithelial cell adhesion molecule) • NANOG (Nanog Homeobox) • BMF (Bcl2 Modifying Factor)
    |
    CD44 expression • EPCAM expression
    2ms
    Miniaturized protein profiling permits targeted signaling pathway analysis in individual circulating tumor cells to improve personalized treatment. (PubMed, J Transl Med)
    The ZeptoCTC workflow represents a valuable tool in single cell cancer research, crucial for personalized medicine. It permits detailed analysis of key proteins and their activation status of targeted, cancer-driven signaling pathways in single cell samples, aiding in understanding tumor response, progression, and treatment efficacy beyond bulk analysis. The method significantly advances clinical investigations in cancer, improving treatment precision and effectiveness. The workflow will be applicable to protein analysis on other types of single cells like relevant in stem cell, neuropathology and hemopoietic cell research.
    Journal • Circulating tumor cells • Tumor cell
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    EPCAM expression
    |
    Truqap (capivasertib)
    2ms
    Identification of HEPACAM2 as a novel and specific marker of small cell carcinoma. (PubMed, Cancer)
    With its remarkable specificity, high expression, presence in early disease, and extracellular secretion, HEPACAM2 could be a potential diagnostic cell surface biomarker for early SCLC detection. These findings warrant further investigation into its role in the pathobiology of SCLC.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
    |
    MYC expression • EPCAM expression
    2ms
    Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia. (PubMed, J Hematol)
    The FC analysis of the peripheral blood allowed the rapid characterization of a non-hematological neoplastic cell population, circulating at unusually high frequency and mimicking an acute myeloid leukemia. The FC detection of CD45-negative cell populations in peripheral blood, bone marrow or lymph node aspirate should prompt the setup of an immunophenotyping panel including EpCAM, CD9, CD56 and CD117, to allow for a rapid and accurate identification of ectopic malignant epithelial cells.
    Journal • IO biomarker • Tumor cell
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • EPCAM (Epithelial cell adhesion molecule) • SDC1 (Syndecan 1) • CD9 (CD9 Molecule) • TFRC
    |
    CD38 positive • NCAM1 expression • CD9 expression • SDC1 positive • EPCAM expression
    2ms
    Double hook-type aptamer-based colorimetric and electrochemical biosensor enables rapid and robust analysis of EpCAM expression. (PubMed, Biosens Bioelectron)
    We successfully employed this nonenzymatic aptasensor for monitoring EpCAM expression in three breast cancer cell lines, which provides an economical and robust alternative to costly and empirical flow cytometry. The dual-signal readout nonenzymatic aptasensor provides rapid, robust, and promising technological support for the accurate management of tumors.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    6ms
    Sorted-cell sequencing on HCC specimens reveals EPS8L3 as a key player in CD24/CD13/EpCAM-triple positive, stemness-related HCC cells. (PubMed, Cell Mol Gastroenterol Hepatol)
    Furthermore, using Akt inhibitor MK2206, we showed that Akt-signaling-driven SP1 drove the expression of the three LCSC markers Our findings suggest that Akt-signaling-driven SP1 promotes EPS8L3 expression, which is critical in maintaining the downstream expression of CD24, CD13 and EpCAM. The findings provide insight into potential LCSC-targeting therapeutic strategies.
    Journal
    |
    CD24 (CD24 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    CD24 expression • EPCAM expression
    |
    MK-2206
    7ms
    Single-cell SERS imaging of dual cell membrane receptors expression influenced by extracellular matrix stiffness. (PubMed, J Colloid Interface Sci)
    The results elucidate the heterogeneity of membrane receptors expression of cells cultured on the substrates with different stiffness. This single-cell analysis method offers an in-situ platform for investigating the impacts of extracellular matrix stiffness on the expression of membrane receptors, providing insights into the role of cell membrane receptors in cancer metastasis.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • PTK7 (Protein Tyrosine Kinase 7)
    |
    EPCAM expression
    7ms
    YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis. (PubMed, J Gene Med)
    YBX1 is upregulated in ICC and promotes stemness and cisplatin insensitivity via the AKT/β-catenin axis. Our study describes a novel potential therapeutic target for improving ICC prognosis.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • EPCAM (Epithelial cell adhesion molecule) • POU5F1 (POU Class 5 Homeobox 1) • SOX9 (SRY-Box Transcription Factor 9) • YBX1 (Y-Box Binding Protein 1)
    |
    EPCAM expression • YBX1 overexpression
    |
    cisplatin • Truqap (capivasertib)
    7ms
    Curcumin-loaded liposomes modulating the synergistic role of EpCAM and estrogen receptor alpha in lung cancer management. (PubMed, Pathol Res Pract)
    An in vitro analysis of the A549 human lung adenocarcinoma cell line identified that CUR-PLXZ at a dose of 5 μM effectively inhibited the expression of EpCAM and ERα. This finding paves the way for targeted intervention strategies in LC management.
    Journal
    |
    ER (Estrogen receptor)
    |
    EPCAM expression
    7ms
    Dual-Aptamer Recognition of DNA Logic Gate Sensor-Based Specific Exosomal Proteins for Ovarian Cancer Diagnosis. (PubMed, ACS Sens)
    By accurately selecting biomarkers and constructing a dual-targeted exosomal protein detection strategy, the limitation of insufficient specificity of traditional protein markers was circumvented. This work contributed to the development of exosome-based prognosis monitoring in ovarian cancer through the identification of disease-specific exosome protein markers.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • CD24 (CD24 Molecule)
    |
    EPCAM expression
    7ms
    A comprehensive review of the botany, phytochemistry, pharmacology, and toxicology of Murrayae Folium et Cacumen. (PubMed, Front Pharmacol)
    MFC contains a wide range of chemical compounds. Flavonoids and coumarins promote strong pharmacological activity and, are low-toxicity natural phytomedicines that are widely used in medicine, food, ornamentation, and cosmetics, making MFC a promising compound for development and use in the treatment of several medical conditions.
    Review • Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • FOXO3 (Forkhead box O3) • MIR29A (MicroRNA 29a)
    |
    EPCAM expression
    8ms
    Biallelic EPCAM deletions induce tissue-specific DNA repair deficiency and cancer predisposition. (PubMed, NPJ Precis Oncol)
    In contrast, maturation into brain organoids and examination of blood and fibroblasts failed to show similar processes, preserving MMR proficiency. The combined use of iPSC, organoid technologies and functional genomics analyses highlights the potential of cutting-edge cellular and molecular analysis techniques to define processes controlling tumorigenesis and uncovers a new paradigm of tissue-specific MMRD, which affects the clinical management of these patients.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule) • DRD (DNA Repair Deficiency)
    |
    DDR • DRD • EPCAM expression
    8ms
    Salvia officinalis L. exerts oncostatic effects in rodent and in vitro models of breast carcinoma. (PubMed, Front Pharmacol)
    In vitro analyses revealed significant anti-cancer effects of SPGE extract in MCF-7 and MDA-MB-231 cell lines (cytotoxicity, caspase-3/-7, Bcl-2, Annexin V/PI, cell cycle, BrdU, and mitochondrial membrane potential). Our study demonstrates the significant chemopreventive and treatment effects of salvia haulm using animal or in vitro BC models.
    Preclinical • Journal • IO biomarker
    |
    PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR155 (MicroRNA 155) • EPCAM (Epithelial cell adhesion molecule) • MIR21 (MicroRNA 21) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MIR34A (MicroRNA 34a-5p) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • TGFB1 (Transforming Growth Factor Beta 1) • CASP7 (Caspase 7) • MIR210 (MicroRNA 210) • RASSF1 (Ras Association Domain Family Member 1) • ANXA5 (Annexin A5) • MIR145 (MicroRNA 145) • MIR22 (MicroRNA 22) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
    |
    BAX expression • CASP3 overexpression • BAX overexpression • EPCAM expression
    8ms
    BerEP4-Negative Basal Cell Carcinoma: An Immunophenotype Not to Forget. (PubMed, Am J Dermatopathol)
    A 74-year-old woman presented with a BerEP4-negative, but anti-renal cell antibody-positive BCC, and the stark clinical implications of misdiagnosis. This case stresses the importance of considering BerEP4-negative BCC, even when other abnormal features are present.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    8ms
    A landscape of patient-derived cancer-associated fibroblast signals in endometrial cancers. (PubMed, Am J Cancer Res)
    We demonstrate that endometrial CAFs can be cultured in an enzymatic-digestion-independent manner, and their signaling landscape can be mapped toward understanding CAF-TME dialogue. Our data will help unearth the functional relevance of endometrial CAFs in the context of clinical outcomes and designing CAF-inclusive therapy in the future.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule) • VIM (Vimentin) • FAP (Fibroblast activation protein, alpha) • PVR (PVR Cell Adhesion Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • THY1 (Thy-1 membrane glycoprotein) • MMP1 (Matrix metallopeptidase 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • S100A4 (S100 calcium binding protein A4)
    |
    CD8 positive • CD44 expression • CXCL12 expression • VIM expression • EPCAM expression
    8ms
    Acoustophoresis enriches tumor cell clusters from patients with metastatic prostate cancer (AACR 2024)
    Label-free acoustophoresis is a potential method for future non-invasive molecular interrogation of metastatic cancers. We believe Acoustophoresis is a promising technology for CTC enrichment with the possibility to detect new subclasses of CTCs as well as cell clusters not detectable with CellSearch. CTC-clusters has previously been proposed as a promising and potent predictor to monitor progressive disease and is associated with earlier onset of metastatic disease and poor prognosis, which makes acoustophoresis ability to identify clusters of high interest.
    Clinical • Tumor cell • Metastases
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule) • CEACAM8 (CEA Cell Adhesion Molecule 8)
    |
    EPCAM expression
    |
    CELLSEARCH®
    8ms
    Molecular and functional characterization of circulating CK+/CD45+ cells in breast cancer (AACR 2024)
    DPcells can have an aberrant genome, supporting their malignancy. Contrary to CTCs, DPcells' CNA profiles are not clonal and, in vivo, they can only be observed in immunocompetent models; both observations support the tumor/immune fusion hypothesis. Finally, DPcells show metastatic potential in mice, in line with the association with worse survival we previously observed in BC pts.
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    |
    CELLSEARCH®
    8ms
    BRD4-targeting PROTACs Synergize With Chemotherapeutics Against Osteosarcoma Cell Lines. (PubMed, Anticancer Res)
    The study suggests that the application of novel BET PROTACs in combination with chemotherapeutics could represent a new therapeutic option to improve the therapy of osteosarcomas. First orally available PROTACs have reached clinical trials.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • AXL (AXL Receptor Tyrosine Kinase) • BCL2L1 (BCL2-like 1) • CDH1 (Cadherin 1) • CA9 (Carbonic anhydrase 9) • VIM (Vimentin) • BRD4 (Bromodomain Containing 4)
    |
    HER-2 expression • CDH1 expression • VIM expression • CA9 expression • EPCAM expression
    |
    cisplatin • gemcitabine • doxorubicin hydrochloride • JQ-1 • topotecan • ARCC-29
    9ms
    Securing LYTAC with Logic-Identification System for Cancer Cell-Selective Membrane Protein Degradation. (PubMed, Small)
    As output, MUC1 is connected to LTR and degraded via lysosome pathway selectively for cancer cell MCF-7 with little side effect on normal cell MCF-10A. The logic-identification system also demonstrated satisfactory in vivo therapeutic results, indicating its promising potential in precise targeted therapy.
    Journal
    |
    MUC1 (Mucin 1) • EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    9ms
    TLR4, IgA and EpCAM Expression in Colorectal Cancer and Their Possible Association with Microbiota as a Pathogenic Factor; An Immunohistochemical and Genetic Study. (PubMed, Asian Pac J Cancer Prev)
    TLR4, IgA, EpCAM expression in both CRC and IBD might be related to the pathogenic role of microbiota and could represent potential prevention modalities and therapeutic targets.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • TLR4 (Toll Like Receptor 4)
    |
    EPCAM expression
    9ms
    The Clonal Relationship and the Clinical Value of EpCAM High-Expressing and Low-Expressing Circulating Tumor Cells in Metastatic Breast Cancer (DKK 2024)
    Our data indicate that EpCAM low-expressing CTCs could be used as a valuable tumor surrogate material – although they may be prognostically less relevant than EpCAM high-expressing CTCs – and have particular benefit if no CTCs are detected using EpCAM dependent technologies.
    Clinical • Circulating tumor cells • Tumor cell • Metastases
    |
    EPCAM (Epithelial cell adhesion molecule) • ITGA6 (Integrin, alpha 6)
    |
    EPCAM expression
    |
    CELLSEARCH®
    9ms
    Interplay in galectin expression predicts patient outcomes in a spatially restricted manner in PDAC. (PubMed, Biomed Pharmacother)
    In summary, the intricate interplay and cell-specific expression patterns of galectins within the PDAC tissue, particularly the inverse correlation between Gal-1 and Gal-4 in ducts and its significant association with patient survival, highlights the complex molecular landscape underlying PDAC and provides valuable insights for future therapeutic interventions.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • LGALS3 (Galectin 3)
    |
    EPCAM expression
    9ms
    Immunolocalization of epithelial cell adhesion molecule and matrix metalloproteinase-9 in oral epithelial dysplasia and oral squamous cell carcinoma. (PubMed, J Cancer Res Ther)
    Correlation between EpCAM and MMP-9 may help to unravel the signaling cascades involved in the carcinomatous changes, tumor cell invasion, and progression of OSCCs.
    Journal
    |
    MMP9 (Matrix metallopeptidase 9)
    |
    EPCAM expression
    9ms
    Functionalized tetrahedral DNA frameworks for the capture of circulating tumor cells. (PubMed, Nat Protoc)
    We further detail the capture of CTCs from patient blood samples. The procedure for the preparation and characterization of n-simplexes requires 11.5 h, CTC capture from clinical samples and data processing requires ~5 h per six samples and the downstream analysis of captured cells typically requires 5.5 h. The protocol is suitable for users with basic expertise in molecular biology and handling of clinical samples.
    Review • Journal • Circulating tumor cells • Tumor cell
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    10ms
    Clonorchis sinensis infection amplifies hepatocellular carcinoma stemness, predicting unfavorable prognosis. (PubMed, PLoS Negl Trop Dis)
    HCC patients with C. sinensis infection exhibit a poor prognosis following hepatectomy. Moreover, C. sinensis infection promotes the acquisition of cancer stem cell-like characteristics, consequently accelerating the malignant progression of HCC.
    Retrospective data • Journal
    |
    AFP (Alpha-fetoprotein) • EPCAM (Epithelial cell adhesion molecule) • KRT19 (Keratin 19) • CA 19-9 (Cancer antigen 19-9)
    |
    AFP elevation • EPCAM expression
    10ms
    Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas. (PubMed, Front Oncol)
    TROP2 constitutes the target for the antibody-drug conjugate Sacituzumab govitecan (SG; TrodelvyTM) which has been approved for treatment of metastatic urothelial carcinoma by the United States Food and Drug administration (FDA) irrespective of its TROP2 expression status...Our data show that TROP2 and EpCAM expression is common and highly interrelated in urothelial neoplasms. Despite of a progressive loss of TROP2/EpCAM during tumor cell dedifferentiation in pTa tumors, the lack of associations with clinicopathological parameters in pT2-4 cancer argues against a major cancer driving role of both proteins for the progression of urothelial neoplasms.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    TROP2 expression • EPCAM expression
    |
    Trodelvy (sacituzumab govitecan-hziy)
    10ms
    Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial. (PubMed, Gynecol Oncol)
    Dual immunotherapy with chemotherapy showed acceptable response rates and tolerable safety in HRR non-mutated PROC, warranting continued clinical investigation.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated) • EPCAM (Epithelial cell adhesion molecule) • FOXP3 (Forkhead Box P3) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
    |
    PD-L1 expression • PD-L1 overexpression • MUC16 mutation • EPCAM expression • PD-L1-L • FOXP3 expression
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab)
    10ms
    Targeting LRRC41 as a potential therapeutic approach for hepatocellular carcinoma. (PubMed, Front Mol Biosci)
    Drug sensitivity analysis and molecular docking shows several FDA-approved drugs may be potential therapeutic targets for HCC. Targeting LRRC41 may hold promise as a potential therapeutic strategy for HCC.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FLT1 (Fms-related tyrosine kinase 1) • CD44 (CD44 Molecule) • EPCAM (Epithelial cell adhesion molecule) • SOX9 (SRY-Box Transcription Factor 9)
    |
    CD44 expression • EPCAM expression • SOX9 expression
    11ms
    EpCAM CAR-T for Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Sichuan University
    Trial completion date • Trial primary completion date • Metastases
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    11ms
    Preoperative Locoregional Therapy May Relate with Stemness and Distinct Transitions Between Epithelial and Mesenchymal States in Hepatocellular Carcinoma. (PubMed, J Clin Exp Hepatol)
    In LRT group, an exclusive association between progenitor/cholangiocytic cell and mesenchymal markers expressed by tumoral cells was observed (P < 0.05): EpCAM tumoral expression associated with vimentin stromal expression; tumoral CK19 expression associated with stromal ASMA expression; tumoral CK7 expression associated with tumoral vimentin expression. Peritumoral cellular proliferation and expression of progenitor/cholangiocytic cell markers seem to be more frequent after LRT, with a distinctive epithelial-mesenchymal interplay and plasticity in peritumoral and tumoral compartments.
    Journal
    |
    TP53 (Tumor protein P53) • EPCAM (Epithelial cell adhesion molecule) • VIM (Vimentin) • KRT19 (Keratin 19)
    |
    TP53 expression • VIM expression • EPCAM expression
    12ms
    Expression of circulating tumour cells in oral squamous cell carcinoma: An ex vivo pilot study. (PubMed, J Oral Maxillofac Pathol)
    The findings of our study suggest that the demonstration of CTCs is feasible and helps in understanding of disease progression and metastatic risk. Sensitive detection of CTCs from blood samples can serve as an implicit tool in early cancer diagnosis and prognosis through liquid biopsy which in itself is minimally invasive and time-saving.
    Preclinical • Journal • Circulating tumor cells • Tumor cell
    |
    CD44 (CD44 Molecule) • EPCAM (Epithelial cell adhesion molecule)
    |
    CD44 expression • EPCAM expression
    12ms
    Beta-Hydroxyisovaleryl-Shikonin Eradicates Epithelial Cell Adhesion Molecule-Positive Liver Cancer Stem Cells by Suppressing dUTP Pyrophosphatase Expression. (PubMed, Int J Mol Sci)
    Taken together, our data suggest that dUTPase could be a good target to eradicate liver CSCs resistant to 5-fluorouracil. β-HIVS is a small molecule that could decrease dUTPase expression and target EpCAM+ liver CSCs.
    Journal • Cancer stem
    |
    EPCAM (Epithelial cell adhesion molecule) • DUT (Deoxyuridine Triphosphatase)
    |
    EPCAM expression
    |
    5-fluorouracil
    12ms
    Glial Cell Adhesion Molecule (GlialCAM) Determines Proliferative Versus Invasive Cell States in Glioblastoma. (PubMed, J Neurosci)
    Quantitative RNA sequencing identifies various GlialCAM-regulated genes with functions in cell-cell adhesion and signaling. These data reveal that GlialCAM and associated signaling partners, including Mlc1 and aquaporin-4, are key factors that determine proliferative and invasive cell states in GBM.
    Journal
    |
    ALCAM (Activated Leukocyte Cell Adhesion Molecule)
    |
    EPCAM expression
    12ms
    HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration. (PubMed, Biomedicines)
    In HER-2-upregulated CRC tissues, CD4, CD8, CD19, CD68, CD11b, Ly6G, and CD56 expressions were elevated (0.70 ± 0.37 vs. 0.32 ± 0.17, p = 0.03; 0.22 ± 0.13 vs. 0.09 ± 0.06, p = 0.03; 0.31 ± 0.19 vs. 0.12 ± 0.08, p = 0.02; 1.05 ± 0.62 vs. 0.43 ± 0.21, p < 0.01; 1.34 ± 0.81 vs. 0.53 ± 0.23, p < 0.01; 0.50 ± 0.31 vs. 0.19 ± 0.10, p < 0.01; 1.26 ± 0.74 vs. 0.52 ± 0.24, p < 0.01). Furthermore, increased HER-2 expression was an independent risk factor for recurrence-free survival (RFS) in patients (p < 0.01, HR = 3.421); The increased expression of HER-2 and its relationship with immune cells will provide new insights for immunotherapy in CRC patients.
    Journal • IO biomarker • Immune cell
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • EPCAM (Epithelial cell adhesion molecule) • CD68 (CD68 Molecule) • ITGAM (Integrin, alpha M)
    |
    HER-2 positive • HER-2 expression • NCAM1 expression • EPCAM expression
    12ms
    EpCAM CAR-T for Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Sichuan University | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    EPCAM expression
    12ms
    Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers (clinicaltrials.gov)
    P1/2, N=11, Terminated, The Hospital for Sick Children | N=50 --> 11 | Trial completion date: Sep 2022 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2022 --> Nov 2023; Withdrawal of drug supply/funding
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • POLD1 (DNA Polymerase Delta 1) • EPCAM (Epithelial cell adhesion molecule) • MSH3 (MutS Homolog 3) • APOB (Apolipoprotein B)
    |
    MSI-H/dMMR • POLE mutation • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression
    |
    Opdivo (nivolumab)
    12ms
    Direct tumor irradiation potentiates adoptive NK cell targeting against parental and stem-like cancer in human liver cancer models. (PubMed, Int J Radiat Oncol Biol Phys)
    NK cells in combination with tumor irradiation can provide synergistic therapeutic effects for NK cell recognition and elimination against both parental and stem-like liver cancer through LFA-1/ICAM-1.
    Preclinical • Journal
    |
    ICAM1 (Intercellular adhesion molecule 1) • CD24 (CD24 Molecule) • TERC (Telomerase RNA Component)
    |
    EPCAM expression
    12ms
    The biomarkers associated with epithelial-mesenchymal transition in human keloids. (PubMed, Burns)
    In summary, this work provides novel EMT biomarkers in keloids and predicts new small target molecules for keloid therapy. Our findings improve the understanding of keloid pathogenesis, providing new treatment options.
    Journal
    |
    MIR155 (MicroRNA 155) • CD24 (CD24 Molecule) • FN1 (Fibronectin 1) • EGF (Epidermal growth factor) • SOX9 (SRY-Box Transcription Factor 9) • CDH2 (Cadherin 2) • KRT19 (Keratin 19) • ITGB1 (Integrin Subunit Beta 1) • KRT18 (Keratin 18) • MIR124-2 (MicroRNA 124-2) • MIR145 (MicroRNA 145) • MIR20A (MicroRNA 20a) • MIRLET7B (MicroRNA Let-7b) • PROM1 (Prominin 1) • MIR124-3 (MicroRNA 124-3)
    |
    miR-155 expression • EPCAM expression
    12ms
    Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model. (PubMed, BMC Cancer)
    We successfully established a PDX model of NGC, to the best of our knowledge, for the first time. The established PDX retained the molecular and transcriptome characteristics of the primary tumour and can be used to predict drug effects. It may facilitate further research and the development of novel therapeutic agents for NGC.
    Preclinical • Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    |
    EPCAM expression
    |
    cisplatin • methotrexate